SOLIGENIX, INC. (SNGX) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases and public health solutions. The company operates two segments: Specialized BioTherapeutics (oncology and inflammation) and Public Health Solutions (biodefense and infectious disease vaccines). This report covers the fiscal year ended December 31, 2025. The company is a smaller reporting company listed on The Nasdaq Capital Market.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $0 | $119,371 |
| Net Loss | $(11,080,380) | $(8,266,576) |
| Research & Development Expenses | $7,485,813 | $5,223,589 |
| General & Administrative Expenses | $4,359,663 | $4,215,908 |
| Cash and Cash Equivalents (Year-End) | $7,936,153 | $7,819,514 |
| Working Capital | $5,149,732 | $3,980,218 |
| Accumulated Deficit | $(245,051,132) | $(233,970,752) |
| Debt | $0 (Fully repaid in Feb 2025) | $1,372,873 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped to zero in 2025 from $119,371 in 2024 due to the conclusion of a zero-margin grant for an investigator-initiated study of HyBryte.
- Increased Net Loss: Net loss increased by 34% ($2.8 million) primarily driven by a 43% increase in R&D expenses ($2.3 million increase) associated with the Phase 2a study for Behçet's Disease (SGX945) and the ongoing confirmatory Phase 3 study for CTCL (HyBryte).
- Debt Repayment: The company fully repaid all outstanding obligations under its convertible debt agreement with Pontifax in February 2025, eliminating interest expense and debt principal from the balance sheet.
- Other Income: Total other income decreased by 66% to $258,481, reflecting a reduction in tax credits and the absence of fair value adjustments on convertible debt.
Guidance, Outlook, and Risks
Going Concern Warning: The company's independent auditors have issued an explanatory paragraph regarding substantial doubt about Soligenix's ability to continue as a going concern. As of the filing date, the company does not have sufficient cash to fund operations for the 12 months following the issuance of financial statements. Management projects cash sufficiency only into the fourth quarter of 2026.
Liquidity Strategy: To mitigate liquidity risks, the company entered into an At-Market Issuance Sales Agreement ("Rodman Sales Agreement") in January 2026, allowing for the sale of up to $3.5 million in common stock. The company also plans to pursue additional government grants and strategic partnerships.
Clinical Pipeline Updates:
- HyBryte (CTCL): Enrollment for the confirmatory Phase 3 "FLASH2" study began in December 2024. Top-line results are anticipated in the second half of 2026. The FDA previously issued a Refusal to File (RTF) letter in 2023, requiring a second Phase 3 trial.
- SGX302 (Psoriasis): Phase 2a study is ongoing with positive preliminary results in Cohorts 2 and 3.
- SGX945 (Behçet's Disease): Phase 2a study completed in July 2025 with positive results; Phase 2 clinical trial planned.
- SGX942 (Oral Mucositis): A second Phase 3 trial is being designed following a Phase 3 study that showed biological activity but did not meet the primary statistical endpoint.
Risks: Key risks include the inability to secure additional financing, failure of clinical trials to meet endpoints, regulatory delays, and geopolitical instability affecting clinical trial sites for Behçet's Disease (specifically in the Middle East).
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate against the "fourth quarter of 2026" projection to assess immediate dilution risk.
- HyBryte Regulatory Path: Confirm the status of discussions with the FDA regarding the development path, given the previous RTF letter and the preference for a comparative study over a placebo-controlled trial.
- Flash2 Enrollment: Monitor the progress of patient enrollment in the FLASH2 study, as top-line results are critical for future valuation and funding.
- ATM Utilization: Track the utilization of the new Rodman Sales Agreement ($3.5 million capacity) to gauge the company's reliance on equity markets.
- Government Funding: Assess the likelihood of securing new government grants for the Public Health Solutions segment, which is currently unfunded for the coming year.